Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN13335 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DBTP-Arm1 | EXPERIMENTAL | - |
| DBTP-Arm2 | EXPERIMENTAL | - |
| DBTP-Arm3 | PLACEBO_COMPARATOR | - |
| OLE-Arm1 | EXPERIMENTAL | - |
| OLE-Arm2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN13335 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Documented clinical diagnosis of PAH (Group 1 PH according to the 7th World Symposium on Pulmonary Hypertension (WSPH)) 2. WHO functional class II or III (slight to marked limitation of functional status due to PAH) 3. Receiving background Standard Of Care (SOC) therapy f...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 5 | PHASE3 | selexipag, Macitentan |
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| IRulya Therapeutics Inc. | IRLA | 1 | PHASE2 | LAM-001 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
REGN13335 is an investigational small molecule being developed by Regeneron Pharmaceuticals for pulmonary arterial hypertension (PAH). It is currently in Phase 2 clinical development and has not been approved by the FDA. It is being studied in adults 18 years and older with PAH.
REGN13335 is being studied for the treatment of pulmonary arterial hypertension (PAH), a cardiovascular condition. It is an investigational therapy and is not approved for any indication. Its only clinical study enrolls adults with PAH and is currently recruiting participants.
REGN13335 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor of the Phase 2 study evaluating the drug in adults with pulmonary arterial hypertension.
REGN13335 is in Phase 2 clinical development. It is investigational and has not received FDA approval. The Phase 2 trial is currently recruiting, with an planned enrollment of 99 participants, and no trials of REGN13335 have been completed to date.
REGN13335 is being evaluated in one clinical trial, NCT07318597, titled Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH). The Phase 2 trial is randomized, double-blind, and placebo-controlled, with an enrollment of 99 adults, and is recruiting across the United States, Australia, Belgium, France, Germany, Latvia, Poland, South Korea, Spain, and the United Kingdom.